Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

  1. Vicente-Valor, J.
  2. Escudero-Vilaplana, V.
  3. Collado-Borrell, R.
  4. López-López, C.
  5. Villanueva-Bueno, C.
  6. Revuelta-Herrero, J.L.
  7. Ruiz-Briones, P.
  8. Somoza-Fernández, B.
  9. Herranz, A.
  10. Sanjurjo, M.
Journal:
Journal of Oncology Pharmacy Practice

ISSN: 1477-092X 1078-1552

Year of publication: 2022

Volume: 28

Issue: 5

Pages: 1259-1263

Type: Article

DOI: 10.1177/10781552221074621 GOOGLE SCHOLAR

Sustainable development goals